KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Cash & Equivalents (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Cash & Equivalents for 16 consecutive years, with $133.8 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 15.51% to $133.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $133.8 million through Dec 2025, up 15.51% year-over-year, with the annual reading at $133.8 million for FY2025, 15.51% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $133.8 million at Halozyme Therapeutics, down from $419.7 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $499.4 million in Q1 2021, with the low at $61.9 million in Q2 2025.
  • Average Cash & Equivalents over 5 years is $213.6 million, with a median of $159.5 million recorded in 2024.
  • The sharpest move saw Cash & Equivalents surged 647.91% in 2021, then plummeted 79.66% in 2022.
  • Over 5 years, Cash & Equivalents stood at $118.7 million in 2021, then soared by 97.27% to $234.2 million in 2022, then crashed by 49.46% to $118.4 million in 2023, then decreased by 2.13% to $115.8 million in 2024, then grew by 15.51% to $133.8 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $133.8 million, $419.7 million, and $61.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.